Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Maxwell

Showing results (131-140 of 200) with videos related to

Pageof 20
Sort By:
Molecular Cancer Research : MCR|May 18, 2026
Variation at the R181 residue of p53 confers loss of p53 DNA binding cooperativity with the retention of mitochondrial-associated apoptosisRenyta Moses, Alexandra Indeglia, Alison S Levine, et al.
JAMA Network Open|March 19, 2024
Neighborhood Deprivation, Race and Ethnicity, and Prostate Cancer Outcomes Across California Health Care SystemsAnanta Wadhwa, Charlotte Roscoe, Elizabeth A Duran, et al.
Breast Cancer Research and Treatment|June 28, 2017
Erratum to: Comparative clinical utility of tumor genomic testing and cell-free DNA in metastatic breast cancerKara N Maxwell, Danielle Soucier-Ernst, Emin Tahirovic, et al.
Biorxiv : the Preprint Server for Biology|August 20, 2025
Variation at the R181 residue of p53 confers loss of p53 DNA binding cooperativity with the retention of mitochondrial-associated apoptosisRenyta Moses, Alexandra Indeglia, Alison S Levine, et al.
Leukemia|July 1, 2021
Germline POT1 variants can predispose to myeloid and lymphoid neoplasmsTristan L Lim, David B Lieberman, Adam R Davis, et al.
The American Journal of Gastroenterology|February 25, 2026
Colorectal neoplasia rates in Li Fraumeni SyndromeSophia R Spiegel, Caitlin Orr, Nicolas U Edgar, et al.
Cancer|January 30, 2026
Remote delivery of cancer genetic testing in veterans with metastatic prostate cancer: A Million Veteran Program pilot studyBruce Montgomery, Julie A Lynch, Jessica Brown, et al.
Human Mutation|June 3, 2020
Suggested application of HER2+ breast tumor phenotype for germline TP53 variant classification within ACMG/AMP guidelinesCristina Fortuno, Jessica Mester, Tina Pesaran, et al.
Journal of the National Cancer Institute|May 3, 2024
Identification of TP53 germline variants in pediatric patients undergoing tumor testing: strategy and prevalenceMinjie Luo, Derek Wong, Kristin Zelley, et al.
The Journal of Clinical Investigation|July 14, 2020
Genomic landscape of metastatic breast cancer identifies preferentially dysregulated pathways and targetsMatt R Paul, Tien-Chi Pan, Dhruv K Pant, et al.
Pageof 20

Showing results (131-140 of 200) with videos related to

Sort By:
Pageof 20
Molecular Cancer Research : MCR|May 18, 2026
Variation at the R181 residue of p53 confers loss of p53 DNA binding cooperativity with the retention of mitochondrial-associated apoptosisRenyta Moses, Alexandra Indeglia, Alison S Levine, et al.
JAMA Network Open|March 19, 2024
Neighborhood Deprivation, Race and Ethnicity, and Prostate Cancer Outcomes Across California Health Care SystemsAnanta Wadhwa, Charlotte Roscoe, Elizabeth A Duran, et al.
Breast Cancer Research and Treatment|June 28, 2017
Erratum to: Comparative clinical utility of tumor genomic testing and cell-free DNA in metastatic breast cancerKara N Maxwell, Danielle Soucier-Ernst, Emin Tahirovic, et al.
Biorxiv : the Preprint Server for Biology|August 20, 2025
Variation at the R181 residue of p53 confers loss of p53 DNA binding cooperativity with the retention of mitochondrial-associated apoptosisRenyta Moses, Alexandra Indeglia, Alison S Levine, et al.
Leukemia|July 1, 2021
Germline POT1 variants can predispose to myeloid and lymphoid neoplasmsTristan L Lim, David B Lieberman, Adam R Davis, et al.
The American Journal of Gastroenterology|February 25, 2026
Colorectal neoplasia rates in Li Fraumeni SyndromeSophia R Spiegel, Caitlin Orr, Nicolas U Edgar, et al.
Cancer|January 30, 2026
Remote delivery of cancer genetic testing in veterans with metastatic prostate cancer: A Million Veteran Program pilot studyBruce Montgomery, Julie A Lynch, Jessica Brown, et al.
Human Mutation|June 3, 2020
Suggested application of HER2+ breast tumor phenotype for germline TP53 variant classification within ACMG/AMP guidelinesCristina Fortuno, Jessica Mester, Tina Pesaran, et al.
Journal of the National Cancer Institute|May 3, 2024
Identification of TP53 germline variants in pediatric patients undergoing tumor testing: strategy and prevalenceMinjie Luo, Derek Wong, Kristin Zelley, et al.
The Journal of Clinical Investigation|July 14, 2020
Genomic landscape of metastatic breast cancer identifies preferentially dysregulated pathways and targetsMatt R Paul, Tien-Chi Pan, Dhruv K Pant, et al.
Pageof 20